Russell Investments Group Ltd. Has $1.71 Million Stake in Irhythm Technologies Inc (IRTC)

Russell Investments Group Ltd. lifted its position in Irhythm Technologies Inc (NASDAQ:IRTC) by 60.2% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 33,054 shares of the company’s stock after acquiring an additional 12,422 shares during the quarter. Russell Investments Group Ltd. owned 0.15% of Irhythm Technologies worth $1,713,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in IRTC. Advisor Group Inc. lifted its holdings in Irhythm Technologies by 763.9% during the 3rd quarter. Advisor Group Inc. now owns 2,920 shares of the company’s stock valued at $151,000 after buying an additional 2,582 shares in the last quarter. Legal & General Group Plc lifted its holdings in Irhythm Technologies by 131.0% during the 2nd quarter. Legal & General Group Plc now owns 3,373 shares of the company’s stock valued at $143,000 after buying an additional 1,913 shares in the last quarter. Voya Investment Management LLC bought a new stake in Irhythm Technologies during the 2nd quarter valued at about $274,000. GSA Capital Partners LLP bought a new stake in Irhythm Technologies during the 2nd quarter valued at about $289,000. Finally, Nationwide Fund Advisors lifted its holdings in Irhythm Technologies by 92.8% during the 2nd quarter. Nationwide Fund Advisors now owns 7,843 shares of the company’s stock valued at $333,000 after buying an additional 3,774 shares in the last quarter. Hedge funds and other institutional investors own 97.80% of the company’s stock.

Irhythm Technologies Inc (NASDAQ IRTC) opened at $51.16 on Monday. The company has a debt-to-equity ratio of 0.38, a current ratio of 7.65 and a quick ratio of 7.57. Irhythm Technologies Inc has a 12-month low of $27.15 and a 12-month high of $57.90. The stock has a market cap of $1,172.52, a P/E ratio of -42.99 and a beta of 2.64.

Irhythm Technologies (NASDAQ:IRTC) last issued its quarterly earnings data on Wednesday, November 1st. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.05. Irhythm Technologies had a negative net margin of 27.56% and a negative return on equity of 27.67%. The firm had revenue of $25.04 million for the quarter, compared to the consensus estimate of $24.30 million. During the same quarter in the previous year, the firm earned ($2.80) EPS. The company’s quarterly revenue was up 49.2% compared to the same quarter last year. research analysts forecast that Irhythm Technologies Inc will post -1.17 earnings per share for the current year.

In other Irhythm Technologies news, CFO Matthew C. Garrett sold 1,193 shares of Irhythm Technologies stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $55.00, for a total transaction of $65,615.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Vijay K. Lathi sold 150,000 shares of Irhythm Technologies stock in a transaction that occurred on Thursday, December 7th. The shares were sold at an average price of $52.57, for a total transaction of $7,885,500.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 493,623 shares of company stock worth $25,794,521. Insiders own 23.30% of the company’s stock.

A number of brokerages recently weighed in on IRTC. Zacks Investment Research lowered shares of Irhythm Technologies from a “hold” rating to a “sell” rating in a report on Tuesday, September 12th. BidaskClub lowered shares of Irhythm Technologies from a “hold” rating to a “sell” rating in a report on Thursday, December 14th. Canaccord Genuity lifted their price objective on shares of Irhythm Technologies from $55.00 to $59.00 and gave the company a “buy” rating in a report on Thursday, November 2nd. ValuEngine upgraded shares of Irhythm Technologies from a “sell” rating to a “hold” rating in a report on Saturday, October 21st. Finally, Royal Bank of Canada began coverage on shares of Irhythm Technologies in a report on Monday, December 4th. They set an “outperform” rating and a $79.00 price objective for the company. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and three have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $65.25.

WARNING: This article was reported by Community Financial News and is owned by of Community Financial News. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The original version of this article can be accessed at https://www.com-unik.info/2017/12/25/russell-investments-group-ltd-has-1-71-million-stake-in-irhythm-technologies-inc-irtc.html.

About Irhythm Technologies

iRhythm Technologies, Inc is a United States-based digital health company. The Company develops and commercializes solutions that integrate biosensor technology, patient data, analytics and medical expertise. The Company offers flagship solution, the ZIO Service. Its ZIO Service consists of the ZIO XT Patch, algorithms and the ZIO Report.

Want to see what other hedge funds are holding IRTC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Irhythm Technologies Inc (NASDAQ:IRTC).

Institutional Ownership by Quarter for Irhythm Technologies (NASDAQ:IRTC)

What are top analysts saying about Irhythm Technologies? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Irhythm Technologies and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit